Type(s) of biological therapy-Pertuzumab (Perjeta) Posts on Medivizor
Navigation Menu

Type(s) of biological therapy-Pertuzumab (Perjeta) Posts on Medivizor

Comparing the effectiveness and safety of combined therapy of pertuzumab with trastuzumab versus single trastuzumab therapy in patients with HER2-positive advanced breast cancer

Comparing the effectiveness and safety of combined therapy of pertuzumab with trastuzumab versus single trastuzumab therapy in patients with HER2-positive advanced breast cancer

Posted by on Nov 14, 2022 in Breast cancer | 0 comments

In a nutshell The study compared the effectiveness and safety of pertuzumab (Perjeta) and trastuzumab (Herceptin) combined therapy with trastuzumab alone in patients with HER2-positive (HER2+) advanced breast cancer (BC). The study found that the combined therapy was more effective and well tolerated compared to single therapy in...

Read More

Searching for patients with advanced HER2 positive breast cancer to test a breast cancer vaccine

Posted by on May 11, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 trial will investigate the safety of pembrolizumab (Keytruda) in combination with VRP-HER2 vaccination in HER2-positive breast cancer (BC).   The main outcomes will be the response of the immune system, clinical response, and side effects. This trial will be taking place in North Carolina, the U.S.  The...

Read More

Adding anthracyclines or carboplatin to standard treatment of breast cancer

Adding anthracyclines or carboplatin to standard treatment of breast cancer

Posted by on Nov 17, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to find out which medication is better for treating HER-2 positive breast cancer, a class of medicines called anthracyclines plus trastuzmab (Herceptin) and pertuzmab (Perjeta), or carboplatin (Paraplatin) plus trastuzmab and pertuzmab. The study found that both medications worked equally as well as each other, but the...

Read More

Comparing neoadjuvant options for HER2+ breast cancer

Posted by on Sep 10, 2017 in Breast cancer | 0 comments

In a nutshell This study aimed to compare the pathological complete response (pCR) rates of two neoadjuvant therapy combinations for HER2 positive (HER2+, dependent on HER2 for growth) breast cancer. This study concluded that the combination of pertuzumab (Perjeta), trastuzumab (Herceptin) and chemotherapy resulted in higher pCR rates than...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor